Study of garetosmab for children with fibrodysplasia ossificans progressiva
Part of Bones, joints & muscles, Genetic & congenital, Hormones & metabolism, Skin clinical trials.
This trial tests a new drug called garetosmab in children and teens with fibrodysplasia ossificans progressiva (FOP), a rare condition where muscle and soft tissue turn into bone. The goal is to see if garetosmab can help prevent or slow down these abnormal bone growths.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 2 and 17 years old (children in the US must be 4 or older).
- You must have a confirmed diagnosis of FOP.
- You must weigh more than 66 pounds (for most participants) or be 66 pounds or less for a separate group.
- You cannot have severe joint involvement (your doctor will check).
- You cannot have had cancer or serious bleeding problems.
- You must be free of significant infections and not need oxygen or respiratory support.
- If you've been on palovarotene, you must have been off it for at least 30 days or 5 half-lives before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks the long-term safety and how well palovarotene works in people with FOP who are already taking it as part of their regular care. By joining, you help doctors learn more about the medicine over time.
This Phase 2 study tests whether INCB000928 can safely help people with fibrodysplasia ossificans progressiva (FOP). It mainly looks at whether the treatment is effective and well-tolerated, and it involves scheduled whole-body scans using low-dose X-rays.
This study tests whether a drug called apitegromab can help improve muscle function in people with facioscapulohumeral muscular dystrophy (FSHD). It is for adults aged 18-60 who have mild to moderate symptoms and can walk or run 10 meters in 5 seconds or less.
This trial is a registry that collects information from people with fibrodysplasia ossificans progressiva (FOP). It helps researchers better understand the condition and use that knowledge for future studies that could lead to better care.
This trial is for people with FOP who have severe, frequent flare-ups. It follows those who are already starting an anti-IL1 medication (like anakinra) to see if it helps reduce flares and improve symptoms.
This trial tests a gene therapy that uses a child's own stem cells to treat autosomal recessive osteopetrosis (a genetic bone disease). It aims to improve bone health and reduce complications like fractures and vision loss.
Hear when a new Fibrodysplasia Ossificans Progressiva trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.